Your browser does not support iframes.
This webpage has the following sections:
Teva’s general criteria for specialty medicines
Drug modalities of interest
Current therapeutic areas of interest and enabling technologies
TEVA’S GENERAL CRITERIA FOR SPECIALTY MEDICINES:We evaluate opportunities using the following criteria:
Addresses significant unmet medical need
DRUG MODALITIES OF INTEREST:
CURRENT THERAPEUTIC AREAS OF INTEREST AND ENABLING TECHNOLOGIES:
A. Late-stage opportunities Teva wants to hear about on- or near- market opportunities that complement our commercial presence across all therapeutic areas and across all our commercial regions. Please feel free to contact us should you have a late-stage opportunity.B. Central nervous system (CNS)
Our respiratory portfolio is both broad and deep, occupying a leading position in this therapeutic area. In 2016 and 2017 we received approvals for a range of new products, including: ProAir Respiclick®, AirDuoTM RespiClick®, ArmonAirTM RespiClick® and Cinqair®. Additionally, in 2015, we completed the acquisition of the CareTRx platform (Gecko Health Innovations) in support of building a suite of connected solutions to further engage our patients and physicians and enhance disease management.
E. BiosimilarsTeva understands the potential biosimilars have as a growth driver to our long term strategy. We currently have 3 marketed biosimilar products Eporatio (epoetin theta), Ovaleap® (follitropin alfa) and Tevagrastim (filgrastim) and in 2016 entered into a partnership with Celltrion for US and Canadian rights to their biosimilar programs for Rituxan® (rituximab) and Herceptin® (trastuzumab). Successful biosimilar opportunities would have the following attributes:
F. Personalized medicine solutions, e.g. diagnostics, prognostics and predictor assaysTeva is interested in technologies that support our therapeutic areas from early diagnosis, subtyping, prognosis and prediction, through to disease monitoring, e.g. prognosing upcoming exacerbations. All development stages of personalized medicine solutions (biomarkers and digital markers included) are relevant. Primary interest is focused on:
G. Technologies and patient solutionsTeva is also interested in cutting edge technologies. We executed a deal with Microchips and the CareTRx (Gecko Health Innovations) platform
Teva wants to hear from you!Our business development activities are led by pharmaceutical professionals with extensive experience in managing discussions, structuring deals and executing agreements.Please feel free to send us your opportunities through the email below. We are committed to provide timely feedback.